Financhill
Sell
34

XPH Quote, Financials, Valuation and Earnings

Last price:
$42.96
Seasonality move :
0.25%
Day range:
$43.07 - $43.97
52-week range:
$38.88 - $48.76
Dividend yield:
1.61%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
58.3K
Avg. volume:
61.3K
1-year change:
9.21%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Analysts' Opinion

  • Consensus Rating
    SPDR S&P Pharmaceuticals ETF has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Downside
    According to analysts' consensus price target of --, SPDR S&P Pharmaceuticals ETF has an estimated downside of -- from its current price of $43.42.
  • Price Target Upside
    According to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $43.42.

Fair Value

  • According to the consensus of 0 analysts, SPDR S&P Pharmaceuticals ETF has -- downside to fair value with a price target of -- per share.

XPH vs. S&P 500

  • Over the past 5 trading days, SPDR S&P Pharmaceuticals ETF has overperformed the S&P 500 by 0.57% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • SPDR S&P Pharmaceuticals ETF does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • SPDR S&P Pharmaceuticals ETF has grown year-over-year revenues for 0 quarters straight. In the most recent quarter SPDR S&P Pharmaceuticals ETF reported revenues of --.

Earnings Growth

  • SPDR S&P Pharmaceuticals ETF has grown year-over-year earnings for 0 quarters straight. In the most recent quarter SPDR S&P Pharmaceuticals ETF reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-23 2023-12-23 2023-12-23
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -- -- -- -- --
EBITDA -- -- -- -- --
Diluted EPS -- -- -- -- --
Period Ending 2020-12-23 2021-12-23 2022-12-23 2023-12-23
Balance Sheet
Current Assets -- -- -- -- --
Total Assets -- -- -- -- --
Current Liabilities -- -- -- -- --
Total Liabilities -- -- -- -- --
Total Equity -- -- -- -- --
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-23 2023-12-23 2023-12-23
Cash Flow Statement
Cash Flow Operations -- -- -- -- --
Cash From Investing -- -- -- -- --
Cash From Financing -- -- -- -- --
Free Cash Flow -- -- -- -- --
XPH
Sector
Market Cap
--
--
Price % of 52-Week High
89.05%
--
Dividend Yield
1.61%
--
Shareholder Yield
--
--
1-Year Price Total Return
9.21%
--
Beta (5-Year)
0.759
--
Dividend yield:
1.61%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $44.13
200-day SMA
Buy
Level $42.91
Bollinger Bands (100)
Sell
Level 43.26 - 46.32
Chaikin Money Flow
Buy
Level 15.4M
20-day SMA
Sell
Level $45.23
Relative Strength Index (RSI14)
Sell
Level 34.79
ADX Line
Sell
Level 9.47
Williams %R
Buy
Level -86.3425
50-day SMA
Sell
Level $45.94
MACD (12, 26)
Sell
Level -0.65
25-day Aroon Oscillator
Sell
Level -72
On Balance Volume
Neutral
Level 16.2M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (8)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Stock Forecast FAQ

In the current month, XPH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XPH average analyst price target in the past 3 months is --.

  • Where Will SPDR S&P Pharmaceuticals ETF Stock Be In 1 Year?

    According to analysts, the consensus estimate is that SPDR S&P Pharmaceuticals ETF share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About SPDR S&P Pharmaceuticals ETF?

    Analysts are divided on their view about SPDR S&P Pharmaceuticals ETF share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that SPDR S&P Pharmaceuticals ETF is a Sell and believe this share price will rise from its current level to --.

  • What Is SPDR S&P Pharmaceuticals ETF's Price Target?

    The price target for SPDR S&P Pharmaceuticals ETF over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is XPH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for SPDR S&P Pharmaceuticals ETF is a Buy. 0 of 0 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of XPH?

    You can purchase shares of SPDR S&P Pharmaceuticals ETF via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase SPDR S&P Pharmaceuticals ETF shares.

  • What Is The SPDR S&P Pharmaceuticals ETF Share Price Today?

    SPDR S&P Pharmaceuticals ETF was last trading at $42.96 per share. This represents the most recent stock quote for SPDR S&P Pharmaceuticals ETF. Yesterday, SPDR S&P Pharmaceuticals ETF closed at $43.42 per share.

  • How To Buy SPDR S&P Pharmaceuticals ETF Stock Online?

    In order to purchase SPDR S&P Pharmaceuticals ETF stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is down 0.09% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 7.53% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 6.1% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock